Dr. Peter Diamandis

Sitting is the use of smoking. Yeah.

Sitting is the use of smoking. Yeah.

Yeah. So when I wake up in the morning, the very first thing I do is give gratitude. All right. It's like my instant reaction. Thank you for the ability to live another amazing day. And can I contribute the maximum I can? And I just, it's like being excited to see what's going to, you know, there's infinite possibilities we're living in. And just excitement for the day.

Yeah. So when I wake up in the morning, the very first thing I do is give gratitude. All right. It's like my instant reaction. Thank you for the ability to live another amazing day. And can I contribute the maximum I can? And I just, it's like being excited to see what's going to, you know, there's infinite possibilities we're living in. And just excitement for the day.

Yeah. So when I wake up in the morning, the very first thing I do is give gratitude. All right. It's like my instant reaction. Thank you for the ability to live another amazing day. And can I contribute the maximum I can? And I just, it's like being excited to see what's going to, you know, there's infinite possibilities we're living in. And just excitement for the day.

And a lot of the breakthroughs coming are across everything. So I have a $600 million venture fund in biotech called Bold Capital and Bold Longevity Growth.

And a lot of the breakthroughs coming are across everything. So I have a $600 million venture fund in biotech called Bold Capital and Bold Longevity Growth.

And a lot of the breakthroughs coming are across everything. So I have a $600 million venture fund in biotech called Bold Capital and Bold Longevity Growth.

B-O-L-D. And we're in our fourth fund now. And so I see a lot of deals. And then I run something called the Longevity Platinum Trip. Dr. Yanni Psaltis and I scan through 500 companies, and we pick 50. And every year, it's a new crop of 50, and we spend five days. I bring my Abundance 360 members in who want to be part of it, and we meet with the CEOs of all these companies.

B-O-L-D. And we're in our fourth fund now. And so I see a lot of deals. And then I run something called the Longevity Platinum Trip. Dr. Yanni Psaltis and I scan through 500 companies, and we pick 50. And every year, it's a new crop of 50, and we spend five days. I bring my Abundance 360 members in who want to be part of it, and we meet with the CEOs of all these companies.

B-O-L-D. And we're in our fourth fund now. And so I see a lot of deals. And then I run something called the Longevity Platinum Trip. Dr. Yanni Psaltis and I scan through 500 companies, and we pick 50. And every year, it's a new crop of 50, and we spend five days. I bring my Abundance 360 members in who want to be part of it, and we meet with the CEOs of all these companies.

And a lot of the people there are to invest or just learn. And this year or last year, 2024 was the first year we're starting to see instead of theory, actual therapeutics, actual things becoming available. Um, I mean, I can jump into some of them. Yeah. Yeah. No, I want to hear about some of them.

And a lot of the people there are to invest or just learn. And this year or last year, 2024 was the first year we're starting to see instead of theory, actual therapeutics, actual things becoming available. Um, I mean, I can jump into some of them. Yeah. Yeah. No, I want to hear about some of them.

And a lot of the people there are to invest or just learn. And this year or last year, 2024 was the first year we're starting to see instead of theory, actual therapeutics, actual things becoming available. Um, I mean, I can jump into some of them. Yeah. Yeah. No, I want to hear about some of them.

Yeah. So, uh, one of them that I love is a company called Immunus. Um, uh, Dr. Hans Kierstad, this is his fifth company. He's had four increasingly bigger exits. He's brilliant in stem cells. And what he identified was he created an iPSC-derived and an embryonic cell-derived stem cell that he can grow, and it puts out 450 discrete molecules and exosomes consistently. Is this the Muse cell?

Yeah. So, uh, one of them that I love is a company called Immunus. Um, uh, Dr. Hans Kierstad, this is his fifth company. He's had four increasingly bigger exits. He's brilliant in stem cells. And what he identified was he created an iPSC-derived and an embryonic cell-derived stem cell that he can grow, and it puts out 450 discrete molecules and exosomes consistently. Is this the Muse cell?

Yeah. So, uh, one of them that I love is a company called Immunus. Um, uh, Dr. Hans Kierstad, this is his fifth company. He's had four increasingly bigger exits. He's brilliant in stem cells. And what he identified was he created an iPSC-derived and an embryonic cell-derived stem cell that he can grow, and it puts out 450 discrete molecules and exosomes consistently. Is this the Muse cell?

um it's not it's not a new cell but it is a and i'll let him define it when he's ready to release it they just completed so what they've done is that there's 440 actually 440 uh secretome that comes out of these cells he's been able to characterize it consistently produce it and turn it into a drug and the fda has allowed him to use that as a drug so they just completed their phase one two-way study in which they were injecting

um it's not it's not a new cell but it is a and i'll let him define it when he's ready to release it they just completed so what they've done is that there's 440 actually 440 uh secretome that comes out of these cells he's been able to characterize it consistently produce it and turn it into a drug and the fda has allowed him to use that as a drug so they just completed their phase one two-way study in which they were injecting

um it's not it's not a new cell but it is a and i'll let him define it when he's ready to release it they just completed so what they've done is that there's 440 actually 440 uh secretome that comes out of these cells he's been able to characterize it consistently produce it and turn it into a drug and the fda has allowed him to use that as a drug so they just completed their phase one two-way study in which they were injecting